• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Stevanato Group to Participate in Upcoming Investor Conferences

    5/9/25 4:03:00 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care
    Get the next $STVN alert in real time by email

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences.

    • Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of America Securities Healthcare Conference in Las Vegas
    • Wednesday, June 4, 2025, at 1:20 p.m. (CT) – Presentation at the 45th Annual William Blair Growth Stock Conference in Chicago
    • Thursday, June 5, 2025, at 10:30 a.m. (ET) – Fireside chat at the Jefferies Global Healthcare Conference in New York City

    A live webcast of each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

    About Stevanato Group

    Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value-added solutions to clients.

    For more information, please visit: www.stevanatogroup.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250509922877/en/

    Media

    Stevanato Group

    [email protected]

    Investor Relations

    Lisa Miles

    [email protected]

     

    Get the next $STVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STVN

    DatePrice TargetRatingAnalyst
    12/13/2024$28.00Outperform
    Wolfe Research
    12/3/2024$23.00Equal-Weight
    Morgan Stanley
    4/22/2024Outperform
    Exane BNP Paribas
    11/1/2023$39.00 → $29.00Buy → Hold
    Jefferies
    9/26/2023$33.00Overweight
    Stephens
    9/19/2023Market Outperform
    CJS Securities
    8/24/2023$34.00Overweight → Equal-Weight
    Morgan Stanley
    3/9/2022$30.00 → $22.00Overweight
    Morgan Stanley
    More analyst ratings

    $STVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Stevanato Group S.p.A. with a new price target

      Wolfe Research initiated coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $28.00

      12/13/24 8:24:13 AM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

      Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $23.00

      12/3/24 8:38:45 AM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Exane BNP Paribas initiated coverage on Stevanato Group S.p.A.

      Exane BNP Paribas initiated coverage of Stevanato Group S.p.A. with a rating of Outperform

      4/22/24 7:53:28 AM ET
      $STVN
      Medical/Dental Instruments
      Health Care

    $STVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

      SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

      11/14/24 4:06:28 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

      SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

      11/14/24 3:30:56 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Stevanato Group S.p.A.

      SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)

      11/14/24 1:28:35 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care

    $STVN
    SEC Filings

    See more
    • SEC Form 6-K filed by Stevanato Group S.p.A.

      6-K - Stevanato Group S.p.A. (0001849853) (Filer)

      5/8/25 4:10:06 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Stevanato Group S.p.A.

      6-K - Stevanato Group S.p.A. (0001849853) (Filer)

      5/8/25 4:05:09 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Stevanato Group S.p.A.

      6-K - Stevanato Group S.p.A. (0001849853) (Filer)

      5/8/25 4:00:04 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care

    $STVN
    Financials

    Live finance-specific insights

    See more
    • Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025

      Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. First Quarter 2025 Highlights (comparisons to prior-year period) Revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue. Gross profit margin increased 80 basis points to 27.2%. Diluted earnings per share were €0.10, and adjusted diluted earnings per share were €0.10. Adjusted EBITDA margin increased 100 basis points to 22.4%. The Company is maintaining

      5/8/25 6:37:00 AM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025

      Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2025 on Thursday, May 8, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 8, 2025, to discuss financial results. During the call, management will refer to a slide presentation, which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-registrat

      4/24/25 5:15:00 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Stevanato Group Reports Record Revenue of €1,104 Million for Fiscal Year 2024

      - Introduces 2025 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024. Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year period) Revenue for the fourth quarter of 2024 increased 3% to €330.6 million, and high-value solutions represented 40% of total revenue, in line with Company expectations. For the fourth quarter, diluted earnings per share were €0.18, and adjusted diluted earnings per share were €0.19. Adjusted EBITDA margin incre

      3/6/25 6:31:00 AM ET
      $STVN
      Medical/Dental Instruments
      Health Care

    $STVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stevanato Group to Participate in Upcoming Investor Conferences

      Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences. Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of America Securities Healthcare Conference in Las Vegas Wednesday, June 4, 2025, at 1:20 p.m. (CT) – Presentation at the 45th Annual William Blair Growth Stock Conference in Chicago Thursday, June 5, 2025, at 10:30 a.m. (ET) – Fireside chat at the Jefferies Global Healthcare Conference in New York City A live webcast of each event will be a

      5/9/25 4:03:00 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025

      Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. First Quarter 2025 Highlights (comparisons to prior-year period) Revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue. Gross profit margin increased 80 basis points to 27.2%. Diluted earnings per share were €0.10, and adjusted diluted earnings per share were €0.10. Adjusted EBITDA margin increased 100 basis points to 22.4%. The Company is maintaining

      5/8/25 6:37:00 AM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025

      Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2025 on Thursday, May 8, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 8, 2025, to discuss financial results. During the call, management will refer to a slide presentation, which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-registrat

      4/24/25 5:15:00 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care

    $STVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Stevanato Group Announces Results of Annual General Meeting

      -All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th

      5/24/24 4:10:00 PM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Stevanato Group appoints Ugo Gay as Chief Operations Officer

      Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera

      4/4/24 8:00:00 AM ET
      $STVN
      Medical/Dental Instruments
      Health Care
    • Stevanato Group Appoints Riccardo Butta as President, Americas

      The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i

      2/2/22 8:30:00 AM ET
      $STVN
      Medical/Dental Instruments
      Health Care